ZARNESTRA, tipifarnib, R115777

DRUG3 trials

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Conditions

Acute Myeloid LeukemiaBreast CancerMyelodysplastic Syndrome

Phase 2

Study of Tipifarnib as Postconsolidation Therapy for Acute Myeloid Leukemia in Patients 60 Years and Older

CompletedNCT00048503

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Acute Myeloid Leukemia

Start: 2002-06-30End: 2005-11-30Updated: 2010-04-27

Study of Tipifarnib in Patients With High-Risk Myelodysplastic Syndrome (MDS)

CompletedNCT00050154

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Myelodysplastic Syndrome

Start: 2002-07-31End: 2006-05-31Updated: 2010-04-27

Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast Cancer

CompletedNCT00050141

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Breast Cancer

Start: 2002-09-30End: 2008-01-31Updated: 2013-02-01

Related Papers

The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Blood2017-12-085 citations